Ross Bersot, CFA, is an Investment Partner at Bay City Capital and has been with the firm since September 2002. Mr. Bersot focuses on evaluating investment opportunities for the firm. As part of the Pritzker Research Consortia Business Strategy Team, he works to commercialize IP derived from the academic groups' research in neuropsychiatric disorders and neurogenesis. Mr. Bersot was previously an analyst at Jackson Square Partners, L.P. where he evaluated investment opportunities within the healthcare and technology sectors for inclusion in the hedge fund's long/short portfolio of publicly traded stocks. Prior to that, he worked as both an equity and fixed-income analyst and trader at Payden & Rygel Investment Counsel in Los Angeles. In a period of three and a half years, various responsibilities included analysis of the healthcare and technology industries for the firm's small-cap equity portfolios, trading $1.5 billion equity and equity derivatives separate accounts, and working as a member of the team managing a $5 billion global fixed income portfolio. Mr. Bersot currently serves as a director on the board of ReSet Therapeutics and an observer on the board of Epizyme, Inc. He received a BA in Economics from the University of California, Los Angeles.